Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)

NCT02742883 is registered in ClinicalTrials.gov with Burzynski Research Institute as lead sponsor.

NCT NCT02742883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02742883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)
Lead sponsor
Burzynski Research Institute
Phase
Phase 2
Overall status
Suspended
Start date
April 13, 2016
Completion date
March 31, 2028
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse, intrinsic pontine glioma